europeanmedicinesagency
The European Medicines Agency (EMA) recommended the authorization of Novaxovid, a new COVID-19 vaccine by American biotechnology company Novavax, Inc. (NASDAQ:NVAX) to be used in people aged +18 years. It is set to become the fifth vaccine to bolster the world’s arsenal against the pandemic. Q3 2021 hedge fund letters, conferences and more Lined Up For ApprovalAs reported by the Financial Times, the Novaxovid vaccine has received —by consensus and after a thorough evaluation— a positive recommendation by the Human Drugs Committee, as it meets the criteria of efficacy, safety, and quality. The ...
ValueWalk
The European Medicines Agency has been targeted by a cyber attack. The agency - which is the EU's lead authority for evaluating products such as coronavirus vaccines - has confirmed that it has been the victim of an attack. In a statement published on its website, the agency said: "EMA has been the subject of a cyber attack. The agency has swiftly launched a full investigation, in close cooperation with law enforcement and other relevant entities. "EMA cannot provide additional details whilst the investigation is ongoing. Further information will be made available in due course." News of the a...
BANG Showbiz English
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら